David Gasalberti, MD
Radiation Oncology · Vineland, NJNPI 1639565948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Novocure Inc. at 24.1% of the total. Reporting peaked in 2023 at $1,531 and has fallen 78.6% since, to $327 in 2025.
Across 132 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$838
- Seagen Inc.$443
- Bayer$390
- Boston Scientific$182
- Eisai Inc.$173
- AstraZeneca$169
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,39198%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 13 | $838 |
| Seagen Inc. | 17 | $443 |
| Bayer | 21 | $390 |
| Boston Scientific | 2 | $182 |
| Eisai Inc. | 11 | $173 |
| AstraZeneca | 4 | $169 |
| E.r. Squibb & Sons, L.L.C. | 2 | $128 |
| Novartis | 8 | $122 |
| Merck | 7 | $114 |
| Sanofi | 1 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Morphosys, US Inc. | 5 | $73 |
| Teleflex LLC | 2 | $65 |
| Johnson & Johnson | 4 | $62 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Taiho Oncology, Inc. | 4 | $58 |
| AVEO Pharmaceuticals, Inc. | 2 | $50 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| Tactile Systems Technology Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Genmab U.S., Inc. | 2 | $29 |
| Pfizer | 2 | $29 |
| Myovant Sciences Inc. | 2 | $28 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Mevion_medical_systems_inc | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $17 |
| Telix Pharmaceuticals | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Amgen | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,477 in reported general payments places this provider in the 85th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Vineland
- Glenda SmithVineland$662
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Salma JabbourNew Brunswick$163K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
- Timothy ChenPennington$43K
- Brett LewisHackensack$23K
- Sang SimLong Branch$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.